Exhibit 99.2

INVESTOR PRESENTATION November 2021Accelerating MIS SpineCulture | Technology | Accessibility Filed by CHP Merger Corp. pursuant to Rule 425 underthe Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934Subject Company: CHP Merger Corp. (File No. 001-39140)

DISCLAIMER AND CONFIDENTIALITY NOTICE ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 2 In this presentation, “Accelus”, the “Company”, “we”, “us” and “our” mean Integrity Implants Inc. d/b/a Accelus. All amounts are in U.S. dollars unless otherwise indicated. The information contained hereindoes not purport to contain all of the information about the Company or CHP Merger Corp. (“CHP”). The information contained herein has not been independently verified.In connection with the proposed business combination, CHP intends to file with the Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 (the "Registration Statement"), which will include a preliminary proxy statement/prospectus and a definitive proxy statement/prospectus, and other related documents. CHP's stockholders are advised to read, when available, the proxy statement/prospectus included in the Registration Statement, including any amendments thereto, as well as other documents filed with with SEC in connection with the proposed business combination. After the Registration Statement is declared effective, the definitive proxy statement/prospectus and other relevant materials will be mailed to stockholders of CHP as of a record date to be established for voting on the proposed business combination and other matters as may be described in the Registration Statement. Stockholders will be able obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, and other documents filed with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC's website at www.sec.gov, or by directing a request to: CHP Merger Corp., 25 Deforest Avenue, Suite 108, Summit, NJ 07901CHP, Accelus and their respective directors and executive officers may be deemed participants in the solicitation of proxies from CHP's stockholders with respect to the business combination. A list of the names of those directors and executive officers and a description of their interests in CHP will be contained in the Registration Statement when available.No representations or warranties are made or implied with respect to the information contained herein. This presentation contains forward-looking statements with respect to the Company. These forward- looking statements, by their nature, require the Company to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements, including without limitation the successful and timely completion and the commercialization of the products referred to herein. Forward-looking statements are not guarantees of performance. These forward-looking statements, including financial outlooks and strategies or deliverables stated herein, may involve, but are not limited to, comments with respect to the Company’s business or financial objectives, its strategies or future actions, its projections, targets, expectations for financial condition or outlook for operations. Words such as “may”, “will”, “would”, “could”, “expect”, “believe”, “plan”, “anticipate”, “intend”, “estimate”, “continue”, or the negative or comparable terminology, as well as terms usually used in the future and conditional, are intended to identify forward-looking statements. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. These assumptions are considered to be reasonable based on currently available information, but the reader is cautioned that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company and its business. The forward-looking information set forth therein reflects expectations as of the date hereof and is subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Undue reliance should not be placed on forward-looking statements. The forward-looking statements contained in this presentation are expressly qualified by this cautionary statement. This presentation is not intended to form the basis of any investment decision and there can be no assurance that any transaction will be undertaken or completed in whole or in part. The delivery of this presentation shall not be taken as any form of commitment on the part of the Company or its shareholders to proceed with any transaction, and no offers will subject the Company or its shareholders to any contractual obligations before definitive documentation has been executed. The Company reserves the right at any time without prior notice and without any liability to (i) negotiate with one or more prospective investors in accordance with any timetable and on any terms that the Company may decide, (ii) provide different information or access to information to different prospective investors, (iii) enter into definitive documentation and (iv) terminate the process, including any negotiations with any prospective investor without giving any reasons therefor.This presentation does not constitute (i) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination or (ii) an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of CHP, the Company, or any of their respective affiliates. No offering of securities shall be made except by means of a prospecus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

DISCLAIMER AND CONFIDENTIALITY NOTICE ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 2 This presentation includes certain financial measures not presented in accordance with GAAP. These non-GAAP financial measures are not measures of financial performance in accordance with GAAP and may exclude items that are significant in understanding and assessing the Company’s financial results. Therefore, these measures should not be considered in isolation or as an alternative to net income, cash flows from operations or other measures of profitability, liquidity or performance under GAAP. You should be aware that the Company’s presentation of these measures may not be comparable to similarly-titled measures used by other companies. The Company believes these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends in and in comparing the Company’s financial measures with other similar companies. These non-GAAP financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income items are excluded or included in determining these non-GAAP financial measures.This presentation also includes certain projections of non-GAAP financial measures. Due to the high variability and difficulty in making accurate forecasts and projections of some of the information excluded from these projected measures, together with some of the excluded information not being ascertainable or accessible, the Company is unable to quantify certain amounts that would be required to be included in the most directly comparable GAAP financial measures without unreasonable effort. Consequently, no disclosure of estimated comparable GAAP measures is included and no reconciliation of the forward- looking non-GAAP financial measures is included. In addition, these non-GAAP financial measures may be calculated or presented differently than, and may not be comparable to, non-GAAP financial measures disclosed by other companies. This presentation contains forecasts with respect to the Company’s projected financial results, including Revenue and CAGR, for the Company’s fiscal years 2021 through 2025, and the data presented for the fiscal year 2020 is derived from unaudited financials. The Company’s independent auditors have not audited, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this presentation, and accordingly, they did not express an opinion or provide any other form of assurance with respect thereto for the purpose of this presentation. These projections should not be relied upon as being necessarily indicative of future results. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. Accordingly, there can be no assurance that the prospective results are indicative of the future performance of the Company or that actual results will not differ materially from those presented in the prospective financial information or that the prospective financial information will be the same as that presented in future public filings related to the business combination. Inclusion of the prospective financial information in this presentation should not be regarded as a representation by any person that the results contained in such prospective financial information will be achieved. This presentation contains confidential information pertaining to the business, operations, and assets of the Company and the use hereof is governed by the confidentiality agreement (“CA”) or non-disclosure agreement (“NDA”) that has been executed by each recipient. If you are in possession of this presentation, you should familiarize yourself with such CA or NDA before reading, circulating, disclosing or using the presentation. If you have not executed and delivered, or are otherwise not bound by such CA or NDA, you have received this presentation in error. If so, please do not copy or distribute the presentation and return the presentation to the sender hereof.

TODAY’S PRESENTERS CHRIS WALSHCEO & Co-Founder Accelus KEVIN WILLIAMSONChief Financial Officer Accelus JOSEPH SWEDISHChairman CHP Merger Corp. ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 2

INVESTMENT RATIONALEAccelus provides a compelling opportunity for CHP Positive ClinicalOutcomes Attractive Growth Profile, High Gross Margins Affordable,Accessible Solution Leverage CHP’s HealthSystem Relationships Differentiated Platform Disrupting Minimally Invasive Spine Surgery Massive MarketOpportunity ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 2

ACCELUS AT A GLANCEImproving procedures and outcomes, creating favorable economics, and providing broad accessibility Vast underserved market with opportunities to capture share Providing broad accessibility, lowering the cost of care and expanding the market Transformational robotic solution, reducing procedural complexity and accelerating growth Attractive busines model with pull-through revenue opportunities Clinically-impactful, data- driven, cost-effective, enabling implant technology ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 7

Pedicle Screws Lumbar Interbody MISAccess and Other Cervical SIGNIFICANT MARKET OPPORTUNITY SPINAL FUSION MARKET • Large, established addressable marketDemographics support continued market growthGrowing OUS spinal fusion market of $3B+Industry positioned for advancements, disruptionEnabling technologies accelerating growth and becoming must-have assetsOpportunity to capture market share with a truly differentiated platform $6.5B+US MarketOpportunity MIS ProceduresEndoscopic SurgeryExpandable Cages Transition to the ASCRobotics/NavigationAugmented Reality HOT TRENDS $1.7B $2.6B $1.9B ~$380M ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 8

ACCELUS OFFERS A TOTAL MIS IMPLANT SOLUTIONSolutions to address the complete procedure Innovative Expandable Interbody Platform Differentiated and cost-effective solutions with high gross margins Proprietary screw technology with substantial growth potential ProprietaryFixation Systems Allograft comprised demineralized bone matrix (DBM) cortical fibers BiomaterialOfferings Economically attractive robotic solution with sustainable source of consumables revenue Enabling RoboticTechnology * ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 9 *Currently under development** Private labeled product marketed by Accelus **

ADDRESSING THE CONSTRAINTS OF MINIMALLY INVASIVE SPINE PROCEDURESSimpler, safer procedures with more consistent outcomes Reduce procedural complexity…Expand visualization…Increase reproducibility…Reduce radiation…Address inefficiency…Minimize learning curve… Access Without CompromiseAdaptive Geometry + Precision Robotics ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 10

GAME-CHANGING SPINAL IMPLANTS WITH ADAPTIVE GEOMETRY Our MissionSolve the clinical challenges of MIS procedures throughinnovation and enabling technologyThe ProblemMIS implants have chased footprint via trajectory, butresults are mixed and clinical complications remainNerve and Vascular Injuries Subsidence and Non-UnionOur SolutionBidirectional expandable lumbar fusion device, with a minimal insertion profile and maximum expansionClinical ResultsRobust performance and significant clinical outcomes97.4% Fusion Rate* 0 Adverse Effects* 0% Subsidence* Fusion: A Retrospective Analysis of Safety and Performance, Int J Spine Surg. 2020©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 12 *One year follow up study found 96.6% of patients and 97.4% of levels were considered fused, per Coric et al, Bidirectional Expandable Technology for Transforaminal or Posterior Lumbar Interbody

What is Adaptive Geometry? Next-generation solution for MIS proceduresProprietary expandable cage technology, featuring bidirectional expansion of interbody devices Why Does it Matter?Minimal insertion profile with maximum footprint Delivers access through a narrow, neural corridor Respects the natural anatomy of the patientDesigned for improved safety and clinical outcomes* Adaptive GeometryTM in Action Adaptive Geometry Integrated Across the Portfolio *Zero reported subsidence or device-related adverse events (Coric et al, Bidirectional Expandable Technology for Transforaminal TM or Posterior Lumbar Interbody Fusion: A Retrospective Analysis of Safety and Performance, Int J Spine Surg. 2020)©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 13

Broad service offering to address MIS needs 9mm profile expanding to 14 x 14mm 7mm profileEndoscopically Assisted TLIF FlareHawk Family of Spinal Fusion Cages Designed For: 11mm profile expanding to 17 x 14mm Titanium Coated TiHawk7, 9, 11* * Coric et al, Bidirectional Expandable Technology for Transforaminal or Posterior Lumbar Interbody Fusion: A Retrospective Analysis of Safety and Performance, Int J Spine Surg. 2020 Minimal Insertion ProfileMinimizing neural retraction Multiplanar ExpansionWide footprint with no compromise Improved Graft DeliveryOpen architecture for continuous graft delivery 11,000+Cages Implanted 3Clinical Studies 97.4%Fusion Rate* 0Adverse Events* 0%Subsidence* **TiHawk11 anticipated to be available in Q1 2022©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 14

PEDICLE SCREW SYSTEM: ALLOWS PROCEDURAL CAPTURE OpenRobust implants and instrumentation to address complex pathology MISElegant design optimized for seamless percutaneous approach CorticalModular tulip heads with slim profiles facilitate a mid-line approach Telescopic Screw TechnologyProprietary screw technology designed to reduce current frustrations and complications with posterior fixation.Complements robotics platforms. An all-in-one screw delivery system designed to reduce instruments, surgical steps, and radiation. Allows for repositioning of screw trajectory without compromising screw purchase. * *PeriscopeTM under development©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 15

©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 16 Optimized for daily use, witha small 30” x 30” footprintEasier to use, enablingbroader applicationsCompelling solution at one- third to one-fourth of the cost TRANSFORMATIONAL NAVIGATION AND ROBOTIC TARGETING SYSTEM

NAVIGATION AND ROBOTIC TARGETING SYSTEM Surgeons that need robotics are in facilities that can’t afford them The Problem: Cost-Effective WithoutCompromisePrecision navigation robotic targeting system for spine surgery, offered at a fraction of the price of the competition Attractive Surgeon EconomicsRapid system positioning with quick and easy set-up and breakdown allowing surgeons to treat more patients Platform Built for AdaptabilityTechnology designed to expand applications to other spinal surgery procedures Enhanced Ease of UseConstructed to streamline workflows with a simplified, intuitive design, minimizing surgeon training requirements Our Solution: ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 17

ACCELUS ROBOTIC NAVIGATION SYSTEM …WITHOUT COMPROMISE EXTRAORDINARY FEATURES… SMALLERTABLE MOUNTED SYSTEM WITH A NEARFIELD CAMERAFASTER35% REDUCTION IN PROCEDURE TIMECOMPARED TO THE COMPETITION*MORE AFFORDABLEPRICED AT A FRACTION OF THE COSTCOMPARED TO THE COMPETITION ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 18 *Soliman et al, Accuracy and Efficiency of Fusion Robotics Versus Mazor-X in Single-Level Lumbar Pedicle Screw Placement, Cureus Journal of Medical Science. 2021

©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. GLOBAL PATENT PROTECTION 19 PUBLISHED CLINICAL DATA ROBUST PORTFOLIO WITH INNOVATIVE PRODUCT PIPELINE510(k) Pathway: FlareHawk9 LineSider FlareHawk7 TiHawkRobotic System Toro-LToro-P (2022*) Zform (2022*)2-D Robotic System (2022*) Toro-A (2023*) Patent Duration:2033-2039 US PATENTS 25252425 US APPSINT’L PATENTS INT’L APPS 19 PROTECTED INNOVATION PEER REVIEWED, MULTI- CENTER STUDIES ON FLAREHAWK 3 PEER REVIEWED ROBOTIC NAVIGATION STUDY 18 CLINCIAL STUDIES INPROCESS & PROPOSED *Anticipated product launch date

FlareHawk Clinical Studies Published in International Journal of Spine Surgery (IJSS)Three retrospective, peer-reviewed studiesFusion rates commensurate with PLIF and TLIF procedures, minimal complications Navigation and Robotic Targeting SystemPublished in Cureus Journal of Medical ScienceComparison against most commonly used spine robot platform (Mazor-X)Significantly shorter procedure workflow duration (better efficiency)Current in-process and proposed clinical research includes: Pressure distribution comparison against commonly used interbody devicesFlareHawk prospective EURobotic navigation IRB submissionLineSider anti-skiving Robotic navigation endoscopicMIS spondy TLIFRobotic navigation time reductionRobotic navigation Kambin’stargeting Compendium of Published Peer-Reviewed FlareHawk Data Proven workflow efficiencies and time savings when utilizing Accelus’ Robotic system 20 PEER-REVIEWED CLINICAL DATA

EXPANDABLE PLATFORM Inserted with minimal profile 3D Printed endplates Post-packed with bone graft Key Features and Benefits of Toro Platform Lateral (LLIF)Q1 2022 Posterior (PLIF / TLIF)Q4 2022 Anterior (ALIF)Q1 2023 then lifts with wide footprint Adaptive Geometry ReimaginedExpands wide first under minimal load FACILITIATES ENTRANCE INTO LATERAL AND ANTERIOR MARKETS InfinitelyExpandable ©2021 ACCELUS, INC. ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 22

LUMBAR INTERBODY MARKET BY APPROACH Anterior 25% Lateral 18% Posterior57% ~155,000Total Procedures Addressed Today MARKET FOR INTERBODY SPINAL FUSION DEVICES Total U.S. Spinal Fusion market is ~$6.5 billion~500,000 Thoraco-Lumbar procedures250,000+ of which utilize Interbody DevicesInterbody Devices represent a ~2 billionmarket opportunity and growing… Accelus currently only serves Posterior (PLIF/TLIF) procedures, addressing ~63% of procedures and ~57% of the market value SUBSTANTIAL OPPORTUNITY FORGROWTH… Reflects percentage of total market value ($) by surgical approach ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 23

LUMBAR INTERBODY MARKET BY APPROACH ADDITIONAL OPPORTUNITIES • More than 350,000 Cervical Fusion procedures performed annuallyRobot placements positioned to drive LineSider (pedicle screw) sales, which represents the largest segment of the spinal fusion market Reflects percentage of total market value ($) by surgical approach*Does not reflect full product pipeline Toro-Lateral Torp-PLIF/TLIF Toro-ALIF Anterior 25% Lateral 18% Posterior57% 240,000+Total Procedures Addressed by Pipeline ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 24 ROBUST PIPELINE TO FILL OUT INTERBODY PORTFOLIO*Toro expands Accelus’ market opportunity

Procedure Cross-Sale Robot PlacementEconomically attractive option, enabling more surgeons to perform more procedures ATTRACTIVE BUSINESS MODELEnabling technology drives product pull-through Pull-Through Screws Opportunities to capture additional elements of the procedure Closed robotic system drives sales of fixation systems ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 25

Carlsbad, CA ESTABLISHED COMMERCIAL FOOTPRINT Focused Strategy to Accelerate Growth Headquarters Palm Beach, FL Strong CommercialInfrastructureDedicated internal sales forceExternal distributor network Growing talent poolRegionally focusedHeadquarters in Palm Beach, FLCenters of excellence accessible to our entire customer baseWide breadth of hospital approvals CommercializationStrategy ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 26 Rapidly expand sales teamGrow direct sales force in targeted marketsContinue to build capitalsales infrastructureInvest in surgeon training and education programsIncrease procedural captureFocus ASC and enterpriselevel growthPath to expanding spine procedural offerings to drive exclusivity Boulder, CO

AMBULATORY SURGERY CENTER (ASC) MARKET GROWING ASC OPPORTUNITYSpine procedures increasingly moving to ambulatory surgery centers86% of spine surgeons expect to use ASCsSpine surgery is considered the most profitable and cost- effective ASC procedureReimbursement tailwinds expected to continueWin-win-win for patients,payers and providers ENABLING TECHNOLOGIES DRIVING ASC ADOPTION Economically Accessible Solutions Truly Portable Robotic Solution, Providing Ease of Use ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 27 Improved Turnover and Proven Workflow Efficiency* Solves Complicated Issues Simply Enables Outpatient MIS Procedures *Soliman et al, Accuracy and Efficiency of Fusion Robotics Versus Mazor-X in Single-Level Lumbar Pedicle Screw Placement, Cureus Journal of Medical Science. 2021

WYATT GEISTCIO WORLD-CLASS SPINE LEADERSHIP CHRIS WALSHCEO & Co-Founder ALEX LUKIANOVChairman KEVIN WILLIAMSONCFO KEVIN McGANNPresident BLAKE STONEGeneral Counsel ANDREW WOLFCSO BRAD CLAYTONCTO ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 28

GROWTH OPPORTUNITIES Launch NewProduct LinesTargeting 7 to 10 new product launches per year Drive Pull- Through RevenueRobot placement to drive pull-through sales Expand SalesForce RegionallyRapidly expand sales team to capture share Accelerate Adoption in ASCsReduce barriers to movingfusion procedures to ASCs FFooccuusseeddSStrtartaetgeygtoy UtonloUcnk lock Industry Leading Growth International ExpansionGrow in targeted international markets ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 29

2020 2021E 2022E 2023E 2024E 2025E $17M $28M $48M $81M $125M $176M FINANCIAL HIGHLIGHTS $27.5MILLION 2021E REVENUE 80%+ GROSSMARGIN Revenue Forecast4-year GrowthExpectations* 60% 2020 to 2025FORECASTED CAGR GROWING AT $81.0 2023EREVENUE MILLION ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 30 *Revenue projections rounded to the nearest million

INVESTMENT TAKEAWAYS Accelerating Minimally-Invasive Spine Surgery Enabling technologies disrupting minimally invasive spine surgeryVast underserved market with opportunities to capture shareDemonstrated value proposition with compelling clinical data Robust product pipeline addressing a broader market opportunity Compelling business model; pull-through revenue opportunitiesExperienced leadership team and industry thought leaders ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 31

APPENDIX

$27.5 $81.0 2021E Core Products Pipeline*Includes new iterations of FlareHawk and TiHawk products Robot Pull-Through 2023E ACHIEVABLE REVENUE GROWTH Core Product GrowthComprised of our existing lines including:FlareHawk / TiHawk* LineSider Fixation (pedicle screws)Biologics Pipeline ProductsComprised of our near-term anticipated line extensions:Toro Lateral Toro ALIFToro PLIF/TLIF Robot RevenueComprised of robot hardware sales and revenue generated from consumables Pull-Through SalesComprised of sales from Core Products driven by robot placementsDirect pull-through of LineSider Fixationsystems used in conjunction with robotIndirect pull-through of interbody devices through cross-sale opportunities A B C A B C D D ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 33 Commentary Sales of existing products lines are anticipated to be the largest contributor to growth, largely driven by pull-through salesRobot Pull-Through revenue is expected to account for 20% of total sales by 2025

TRANSACTION OVERVIEW Source of Funds Pro Forma Valuation Use of Funds Illustrative Pro Forma Ownership Accelus Rollover Equity CHPM Public Shares 39% 7%CHPM Sponsor SharesNote: Assumes no redemptions. Excludes impact of 1.9 million sponsor earnout shares vesting ratably at $13.00 and $16.00. Excludes impact of 15.0 million public warrants and 8.0 million sponsor warrants (including 1.6 million transferred to Accelus shareholders and 2.0 million subject to earnout ratably at $13.00 and $16.00) struck at $11.50. Includes 2.1 million sponsor shares and 2.2 million sponsor warrants subject to forfeiture if cash delivered is between $150 million and $75 million after redemptions.Estimated transaction fees and expenses for both SPAC and target including advisory, legal, accounting, and other fees.Debt balance reflect Accelus’ current outstanding debt of $9.3 million and an anticipated $6.0 million incremental drawdown from the existing credit facility to fund ordinary course business operations.Pro forma cash balance includes: (i) $2.5 million of existing cash on balance sheet as of November 10, 2021; (ii) $285.0 million of net proceeds from SPAC; (iii) estimated $10.0 million of proceeds from anticipated closing of ongoing Series D financing; (iv) anticipated $6.0 million of proceeds from scheduled incremental drawdown of credit facility to fund ordinary course business operations. Actual pro forma cash balances subject to change. 54% ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 34

COMPELLING VALUATION EV / Revenue 2022E EV / Revenue 2023E Revenue CAGR’21 – ‘23 High Growth Med-Tech 15.9x 12.1x 40% Premium Spine & Orthopedics 9.0x 7.4x 21% Enabling Robotic Technology 25.5x 16.0x 48% Accelus 10.0x 6.0x 72% Source: Wall Street research, company filings and S&P Capital IQ; market data as of November 5, 2021 ©2021 ACCELUS ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 35